Image from Roberto Sorin via Unsplash
The field of pharmacovigilance has evolved significantly in recent years. While regulatory authorities have long favored technologies such as artificial intelligence and machine learning for monitoring patient safety, the trend has accelerated during the pandemic. “I’ve never seen as much advancement as I have in the last two years,” said Marie Flanagan, director, offering management, Vigilance Detect at IQVIA.
Flanagan predicted that regulators’ interest in AI and ML for pharmacovigilance will catalyze growing interest across the pharma industry in 2022 and beyond. The pandemic has demonstrated to regulators and life science companies that the technologies can help make sense of exploding volumes of pharmacovigilance data points.
“If we look at just the user vigilance database in the past two years — as of last week, 64% of all infor…